This study is designed to evaluate the real world efficacy and safety of the liposomal irinotecan (Onivyde®)-based treatment scheme in Chinese patients with locally advanced or metastatic pancreatic cancer, and to compare the efficacy with that of the whole pancreatic cancer population who did not receive relevant treatment.
Age ≥ 18 years old.
Patients with locally advanced or metastatic PDAC diagnosed by pathology.
Patients who received at least one cycle of Nal-IRI (Onivyde®）+ 5-FU/LV treatment.
Patients who have progressed in treatment with gemcitabine or gemcitabine containing regimens in the past.
Confirm pregnant or lactating women.
The patient's clinical data is not available.
The researchers determined that they were not suitable for inclusion in the study due to other circumstances.
RenJi Hospital
Lead sponsor
Servier (Tianjin) Pharmaceutical Co. LTD.
Collaborator